Chronic p38 mitogen-activated protein kinase inhibition improves vascular function and remodeling in angiotensin II-dependent hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 17, Issue 3, 2016, Pages

  Potthoff, S A ^a   Stamer, S ^a   Grave, K ^a   Konigshausen E ^a   Sivritas, S H ^a   Thieme, M ^a   Mori, Y ^a   Woznowski, M ^a   Rump, L C ^a   Stegbauer, J ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Angiotensin II; Animal study; Blood pressure; Hypertension; Kidney; Mice; Mitogen activated protein kinase; Vascular dysfunction

Indexed keywords

8 ISOPROSTANE; ANGIOTENSIN II; DORAMAPIMOD; GELATINASE B; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NORADRENALIN; RNA; PROTEIN KINASE INHIBITOR; S NITROSOGLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTIC MEDIA TO LUMEN RATIO; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; C57BL 6 MOUSE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY PERFUSION; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENOVASCULAR DISEASE; TREATMENT DURATION; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; KIDNEY; PATHOPHYSIOLOGY; PERFUSION; SYSTOLE;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; HYPERTENSION; KIDNEY; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERFUSION; PROTEIN KINASE INHIBITORS; S-NITROSOGLUTATHIONE; SYSTOLE; VASCULAR REMODELING;

EID: 84983315010     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320316653284     Document Type: Article

References (47)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260
2. Schachter M. Changes in the usage of antihypertensive drugs: Implications and prospects. Brit J Clin Pharmacol 2005; 60: 231-234
3. Ikeda N, Sapienza D, Guerrero R, et al. Control of hypertension with medication: A comparative analysis of national surveys in 20 countries. Bull WHO 2014; 92: 10-19
4. Potthoff SA, Fahling M, Clasen T, et al. Angiotensin-(1-7) modulates renal vascular resistance through inhibition of p38 mitogen-activated protein kinase in apolipoprotein E-deficient mice. Hypertension 2014; 63: 265-272
5. Taniyama Y, Ushio-Fukai M, Hitomi H, et al. Role of p38 MAPK and MAPK-APK-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells. Am J Physiol Cell Physiol 2004; 287: C494-499
6. Meloche S, Landry J, Huot J, et al. P38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol Heart Circ Physiol 2000; 279: H741-751
7. Kwon S, Fang LH, Kim B, et al. P38 Mitogen-activated protein kinase regulates vasoconstriction in spontaneously hypertensive rats. J Pharmacol Sci 2004; 95: 267-272
8. Patzak A, Lai EY, Fahling M, et al. Adenosine enhances long-term contractile response to angiotensin II in afferent arterioles. Am J Regul Integrat Comparat Physiol 2007; 293: R2232-2242
9. Wei C, Cardarelli MG, Downing SW, et al. The effect of angiotensin II on mitogen-activated protein kinase in human cardiomyocytes. J Renin-Angiotensin-Aldosterone Syst 2000; 1: 379-384
10. Wang M, Monticone RE and Lakatta EG. Proinflammation of aging central arteries: A mini-review. Gerontology 2014; 60: 519-529
11. Tsioufis C, Dimitriadis K, Selima M, et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 2007; 28: 1162-1169
12. Kyaw M, Yoshizumi M, Tsuchiya K, et al. Antioxidants inhibit JNK and p38 MAPK activation but not ERK 1/2 activation by angiotensin II in rat aortic smooth muscle cells. Hypertens Res 2001; 24: 251-261
13. Ushio-Fukai M, Alexander RW, Akers M, et al. P38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998; 273: 15022-15029
14. Mattace-Raso FU, Van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study. Circulation 2006; 113: 657-663
15. Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34: 1203-1206
16. Palatini P, Casiglia E, Gasowski J, et al. Arterial stiffness, central hemodynamics and cardiovascular risk in hypertension. Vasc Health Risk Manag 2011; 7: 725-739
17. Vlachopoulos C, Aznaouridis K and Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327
18. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241
19. Park JK, Fischer R, Dechend R, et al. P38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 2007; 49: 481-489
20. Stegbauer J, Vonend O, Habbel S, et al. Angiotensin II modulates renal sympathetic neurotransmission through nitric oxide in AT2 receptor knockout mice. J Hypertens 2005; 23: 1691-1698
21. Stegbauer J, Kuczka Y, Vonend O, et al. Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release. Am J Physiol 2008; 294: R421-428
22. Broekmans K, Stegbauer J, Potthoff SA, et al. Angiotensin II-induced hypertension is attenuated by reduction of sympathetic output in NO-sensitive guanylyl cyclase 1 knockout mice. J Pharmacol Exp Therapeut 2016; 356: 191-199
23. Stegbauer J, Potthoff SA, Quack I, et al. Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoprotein E-deficient mice. Br J Pharmacol 2011; 163: 974-983
24. Stegbauer J, Oberhauser V, Vonend O, et al. Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats. Cardiovasc Res 2004; 61: 352-359
25. Joos H, Albrecht W, Laufer S, et al. Differential effects of p38 MAP kinase inhibitors on the expression of inflammation- associated genes in primary, interleukin-1beta-stimulated human chondrocytes. Brit J Pharmacol 2010; 160: 1252-1262
26. Owens AP III, Subramanian V, Moorleghen JJ, et al. Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of the inhibitor of differentiation 3. Circulat Res 2010; 106: 611-619
27. McNulty M, Mahmud A, Spiers P, et al. Collagen type I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 2006; 20: 867-873
28. Castro MM, Rizzi E, Prado CM, et al. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29: 194-201
29. Koffi I, Lacolley P, Kirchengaast M, et al. Prevention of arterial structural alterations with verapamil and trandolapril; and consequences for mechanical properties in spontaneously hypertensive rats. Eur J Pharmacol 1998; 361: 51-60
30. Nishimura A, Sunggip C, Tozaki-Saitoh H, et al. Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertension. Sci Signal 2016; 9: 7
31. Carbone ML, Bregeon J, Devos N, et al. Angiotensin II activates the RhoA exchange factor Arhgef 1 in humans. Hypertension 2015; 65: 1273-1278
32. Ravarotto V, Pagnin E, Maiolino G, et al. The blocking of angiotensin II Type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. J Renin-Angiotensin-Aldosterone Syst 2015; 16: 1245-1250
33. Sparks MA, Stegbauer J, Chen D, et al. Vascular Type 1A angiotensin II receptors control BP by regulating renal blood flow and urinary sodium excretion. J Am Soc Nephrol 2015; 26: 2953-2962
34. Bao W, Behm DJ, Nerurkar SS, et al. Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage and superoxide anion production. J Cardiovasc Pharmacol 2007; 49: 362-368
35. Cheriyan J, Webb AJ, Sarov-Blat L, et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxidemediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 2011; 123: 515-523
36. Ju H, Behm DJ, Nerurkar S, et al. P38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. P38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Therapeut 2003; 307: 932-938
37. Wu J, Thabet SR, Kirabo A, et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circulat Res 2014; 114: 616-625
38. Griendling KK, Berk BC, Ganz P, et al. Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture. Hypertension 1987; 9: III181-185
39. Cortez DM, Feldman MD, Mummidi S, et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK-dependent and ERK1/2-dependent C/EBP-beta, NF-kappaB and AP-1 activation. Am J Physiol Heart Circulat Physiol 2007; 293: H3356-3365
40. Wu Y, Zhu L, Liu L, et al. Interleukin-17A stimulates migration of periodontal ligament fibroblasts via p38 MAPK/NF-kappaB-dependent MMP-1 expression. J Cellul Physiol 2014; 229: 292-299
41. Dange MC, Agarwal AK and Kalraiya RD. Extracellular galectin-3 induces MMP9 expression by activating p38 MAPK pathway via lysosome-associated membrane protein- 1 (LAMP1). Molec Cellul Biochem 2015; 404: 79-86
42. Gilet A, Zou F, Boumenir M, et al. Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways. Exp Cell Res 2015; 331: 152-163
43. Chiao YA, Ramirez TA, Zamilpa R, et al. Matrix metalloproteinase- 9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 2012; 96: 444-455
44. Dayer C and Stamenkovic I. Recruitment of matrix metalloproteinase- 9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase-3 (LH3) triggers TGF-beta activation and fibroblast differentiation. J Biolog Chem 2015; 290: 13763-13778
45. Yao J, Xiong M, Tang B, et al. Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid arteryjugular vein shunt pulmonary hypertension model in rats. Eur J Cardio-thoracic Surg 2012; 42: e121-7
46. Thomas AC and Newby AC. Effect of matrix metalloproteinase- 9 knockout on vein graft remodelling in mice. J Vascular Res 2010; 47: 299-308
47. Li Z, Froehlich J, Galis ZS, et al. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 1999; 33: 116-123